TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04141163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin, 1,1 dimethylbiguanide, or systematic (IUPAC) name N,N-dimethylimidodicarbonimidic diamide, is an oral anti-diabetic medicine approved in the US by the FDA in 1994. It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with other drugs under the names Actoplus Met, Metaglip, Glucovance, Janumet, Kombiglyze XR, and PrandiMet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: No therapeutic effect
Study: NCT01324882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colonoscopy with Olympus Technically Improved Colonoscope
Description: The standard colonoscopy will be performed using the Olympus Technically Improved Colonoscope.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control with standard colonoscope Olympus CF-H180
Description: Standard colonoscopy using the adult scope, Olympus CF-H180.
Study: NCT04100356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise program - indoor bicycle interval exercise, duration 60 min 3x week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise program - indoor bicycle interval exercise, duration 60 min 3x week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Diet
Description: Normal diet recommended by the health authorities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Diet
Description: Normal diet recommended by the health authorities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LCHF Diet
Description: LCHF Diet, a modified Atkins diet with high percentage of fat and very low percentage of karbohydrates

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LCHF Diet
Description: LCHF Diet, a modified Atkins diet with high percentage of fat and very low percentage of karbohydrates
Study: NCT03286205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV iron
Description: IV iron infusion based on weekly or every 3 week dosage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV iron
Description: IV iron infusion based on weekly or every 3 week dosage.
Study: NCT02181699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK2823
Description: single agent KHK2823
Study: NCT03971357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil
Description: netarsudil opthalmic solution 0.02%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drops
Study: NCT01796977

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OxyGenesys Dissolved Oxygen Dressing

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Gauze Dressing
Study: NCT00071643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy
Description: Problem solving therapy aims to make patients aware of symptoms of problems and link those with behaviors associated with solving them.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Participants will receive escitalopram, a selective serotonin reuptake inhibitor.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a placebo pill.
Study: NCT04228770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meeting with pharmacist
Description: Meeting with pharmacist to support drug management following their routine surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meeting with pharmacist
Description: Meeting with pharmacist to support drug management following their routine surgery.
Study: NCT03157960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blueberry drink
Description: Participant receive blueberry drink

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blueberry and pizza
Description: Participant receive blueberry drink and a slice of pizza

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft beverage
Description: Participant receive a soft beverage drink

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft beverage and pizza
Description: Participant receive a soft beverage drink and a slice of pizza

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Participant receive a drink containing fructose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose and pizza
Description: Participant receive a fructose drink and a slice of pizza
Study: NCT03383471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Invossa K Inj.
Description: Invossa K Inj.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study: NCT00994318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCM (Ferric carboxymaltose) high ferritin target

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCM (Ferric carboxymaltose) low ferritin target

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Iron (Ferrous sulphate)
Study: NCT04306172

Intervention type: OTHER
Intervention: An US Readmission Risk Prediction Model
Description: Logistic regression model that predicts the risk of all-cause unplanned readmissions developed by the privately held healthcare software company EPIC.

Intervention type: OTHER
Intervention: LACE+ score
Description: The LACE+ score is a point score that can be used to predict the risk of post-discharge death or urgent readmission. It was developed based on administrative data in Ontario, Canada.

Intervention type: OTHER
Intervention: LACE+ score
Description: The LACE+ score is a point score that can be used to predict the risk of post-discharge death or urgent readmission. It was developed based on administrative data in Ontario, Canada.
Study: NCT01039844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOC-paclitaxel
Description: Phase I Starting Dose: 100 mg/m\^2 IV (intravenously) 1 hour infusion on Day 1, 8, 15, 22 and 29; and repeated every 42 days (6 weeks) per cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I.
Study: NCT04306172

Intervention type: OTHER
Intervention: SQLAPE model
Description: The readmission risk model (Striving for Quality Level and analyzing of patient expenditures), is a computerized validated algorithm and was developed in 2002 to identify potentially avoidable readmissions.
Study: NCT02836353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Description: Single dose of short acting Somatostatin (100mcg) pre Oral glucose tolerance test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 1 week course of 400mg three times daily (TDS) pre Oral glucose tolerance test
Study: NCT01463891

Intervention type: DRUG
Intervention: Eribulin Mesylate
Description: The usual adult dose of eribulin mesylate is 1.4 mg/m\^2 (body surface area) administered intravenously over 2 to 5 minutes, once daily once a week. Treatment shall be continued for 2 consecutive weeks followed by a third week of drug cessation. With each cycle lasting 3 weeks, the treatment shall be repeated. The dose may be reduced, depending on the condition of the individual patient.
Study: NCT01669824

Intervention type: DRUG
Intervention: Acetylsalicylic acid (Aspirin, BAYE4465)
Description: Aspirin protect (enteric coated aspirin) 100 mg/single dose/day as long-term medication
Study: NCT01000688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin + acarbose
Description: 4 week treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acarbose + vildagliptin
Description: 4 week treatment
Study: NCT04086524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Binocular cartoon treatment at home
Description: see arm description.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: see arm description

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Binocular cartoon treatment in office
Description: see arm description.
Study: NCT00559026

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Melan-A
Description: i.d. injections of Melan-A: 26-35 (A27L) and gp100: 209-217 (210M) peptides (250 µg each) formulated in Montanide ISA-51 plus s.c. injection of 3MU IFN-α, as an adjuvant on day 1 and 8 every 21 days for a total of 5 courses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Melan-A plus Dacarbazine
Description: Dacarbazine plus vaccine: the vaccination schedule as in arm 1 was combined with DTIC (800 mg/mq i.v.) administered one day before each vaccine administration according to the standard treatment.
Study: NCT03467282

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: 1g probiotic mix (twice day): Lactobacillus acidophilus 1x109 CFU + Bifidobacterium lactis 1x109 CFU + Lactobacillus rhamnosus 1x109 CFU + Lactobacillus paracasei 1x109 CFU

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1g polydextrose/maltodextrin - twice day
Study: NCT00304434

Intervention type: DRUG
Group type: OTHER
Intervention: Oseltamivir

Intervention type: DRUG
Group type: OTHER
Intervention: Probenecid
Study: NCT04593303

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal iliac artery ligation with cervicoisthmic compression suture
Description: Retroperitoneal approach will be performed to ligate both internal iliac arteries before bladder dissection followed by cervicoisthmic compression suture application at placental bed

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cervicoisthmic compression suture without Internal iliac artery ligation
Description: Bladder dissection followed by cervicoisthmic compression suture application at placental bed without Internal iliac artery ligation
Study: NCT02159287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: 1 mg of enoxaparin per kilogram of body weight subcutaneous every 12 hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: 1000 unit per hour continuous intravenous infusion of heparin sodium
Study: NCT04413162

Intervention type: OTHER
Group type: OTHER
Intervention: Kinect motion tracking system
Description: Kinect motion tracking system is used to measure shoulder range of motion compared to goniometric measurement.
Study: NCT01151449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00152516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levetiracetam (LEV)
Description: Per protocol oral tablets or oral solution at 10 to 30mg/kg/day bid for 48 weeks, or approximately 52 weeks should a subject choose to discontinue levetiracetam (LEV) at the end of the maintenance period.
Study: NCT01479062

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alive-PD
Description: Weekly email/web goal-setting intervention to improve physical activity, diet and weight loss for pre-diabetics, with additional phone support

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Placebo Control
Study: NCT01691430

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2 cranberry capsules
Description: Two cranberry capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)
Study: NCT01992874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib Capsule (Part A)
Description: Pimasertib capsule administration at a single dose of 60 milligram (mg) orally on Day 1 in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib Tablet (Part A)
Description: Pimasertib tablet administration at a single dose of 60 mg orally on Day 3 in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib Tablet (Part A)
Description: Pimasertib tablet administration at a single dose of 60 mg orally on Day 1 in Part A.
Study: NCT02727413

Intervention type: PROCEDURE
Intervention: Blood sample collection
Description: Drawing of 10 ml blood at inclusion, at the time of CPB connection, 60 min under CPB, at the time of CPB disconnection, 6, 24 and 48 hours post-surgery

Intervention type: PROCEDURE
Intervention: Blood sample collection
Description: Drawing of 10 ml blood at inclusion, at the time of CPB connection, 60 min under CPB, at the time of CPB disconnection, 6, 24 and 48 hours post-surgery
Study: NCT01992874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib Capsule (Part A)
Description: Pimasertib capsule administration at a single dose of 60 mg orally on Day 3 in Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib Capsule (Part B and trial extension phase)
Description: Subjects completing Part A to receive pimasertib capsule at a dose of 60 mg orally twice daily in cycles of 21 days each in Part B and trial extension phase until disease progression, intolerable toxicity, subject withdrawal, loss to follow-up or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib Capsule (Part B and trial extension phase)
Description: Subjects completing Part A to receive pimasertib capsule at a dose of 60 mg orally twice daily in cycles of 21 days each in Part B and trial extension phase until disease progression, intolerable toxicity, subject withdrawal, loss to follow-up or death.
Study: NCT02798419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD05 Cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active01 Cream
Study: NCT01223209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-315
Description: 0.25-2.0 mg/ML, maximum 5 injections during 36 days.
Study: NCT02260635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Evacetrapib
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT02608476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-03-01 cream, 1%
Description: CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
Study: NCT03793296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Device Closure: Vascular plug
Description: percutaneous transcatheter approach into cardiac valve
Study: NCT04245358

Intervention type: DEVICE
Group type: OTHER
Intervention: Ainara
Description: 1g of gel per administration
Study: NCT01465932

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control, no Proprioception
Description: The period of data collection period was from June 2010 to August 2011. All subjects who met the inclusion criteria, were randomly allocated to group 1 (control) or group 2 (experimental). Both groups consisted of 12 physical therapy sessions, taking place 2 times a week for 6 weeks. After randomization, subjects were allocated to group 1 (control group) underwent cervical stretching exercises, strengthening the scapular muscles and rotator cuff and cryotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental, Proprioceptive exercises
Description: The period of data collection period was from June 2010 to August 2011. All subjects who met the inclusion criteria, were randomly allocated to group 1 (control) or group 2 (experimental). Both groups consisted of 12 physical therapy sessions, taking place 2 times a week for 6 weeks. After randomization, subjects were allocated to group 2 (experimental group) underwent cervical stretching exercises, strengthening the scapular muscles and rotator cuff exercises and cryotherapy as well as proprioceptive sensory-motor
Study: NCT02358551

Intervention type: DEVICE
Group type: OTHER
Intervention: Placement of electrode lead through axillary vein puncture

Intervention type: DEVICE
Group type: OTHER
Intervention: Placement of electrode lead through subclavian vein puncture
Study: NCT02246686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STW5-II (Iberogast N, BAY98-7410)
Description: Application over 12 weeks 20 drops three time daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application over 12 weeks 20 drops three time daily
Study: NCT02563418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eye-tracking
Study: NCT04464733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9950
Description: HRS9950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9950
Description: HRS9950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9950
Description: HRS9950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9950
Description: HRS9950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9950
Description: HRS9950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9950
Description: HRS9950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9950
Description: HRS9950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9950
Description: HRS9950
Study: NCT01792609

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maximum Number of Screws
Description: The tools used for this arm of study are FDA approved with section 510 (k) K122433. These screws are regularly used in all procedures pertaining to Cobb angle correction surgeries outside of the context of this study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimum Number of Screws
Description: The tools used for this arm of study are FDA approved with section 510 (k) K122433. These screws are regularly used in all procedures pertaining to Cobb angle correction surgeries outside of the context of this study.
Study: NCT04464733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9950
Description: HRS9950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9950
Description: HRS9950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9950
Description: HRS9950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9950
Description: HRS9950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9950
Description: HRS9950
Study: NCT02727413

Intervention type: OTHER
Intervention: Assessment of signs of organ dysfunction
Description: Assessment of signs of organ dysfunction based on medical data prior to surgery, 24 and 48 hours post-surgery, and at the time of ICU discharge

Intervention type: OTHER
Intervention: Assessment of signs of organ dysfunction
Description: Assessment of signs of organ dysfunction based on medical data prior to surgery, 24 and 48 hours post-surgery, and at the time of ICU discharge
Study: NCT04104334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil infusion, desflurane titration and fluid infusion will be guided by NOL index, BIS index and Flotrac EV1000 system respectively
Description: NOL index will guide the administration of remifentanil to keep the index between 5-25, and the desflurane will be titrated to keep a BIS index between 45 and 55. Cardiac output and stroke volume variation will be measured by the Flotrac EV1000 system. Patients will receive 250ml fluid challenges with a recommended solution as required, in order to achieve a maximal value of stroke volume

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil infusion and desflurane titration will be guided by anesthesia usual practices
Description: Desflurane will be administered to keep MAC at 1, and remifentanil infusion rate will be adapted to the mean arterial blood pressure to keep it between 65 and 100, according to anesthesia usual practices
Study: NCT00395772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto (Rivaroxaban, BAY59-7939)
Description: BAY59-7939 20 mg once daily (od) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto (Rivaroxaban, BAY59-7939)
Description: BAY59-7939 30 mg od for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto (Rivaroxaban, BAY59-7939)
Description: BAY59-7939 40 mg od for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (LMW) Heparin + Vitamin K Antagonist
Description: Low Molecular Weight (LMW) Heparin + Vitamin K Antagonist (VKA) for 5 days, then VKA only for the rest of 12 weeks
Study: NCT04464733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9950
Description: HRS9950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9950
Description: HRS9950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT03797001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: 100 mg subcutaneous injection, daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection, daily for 24 weeks
Study: NCT00809874

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Casein

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Isolate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Hydrolysate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alphalact-Albumin
Study: NCT02321358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two-time implementation intention
Description: Will be given intervention and booster at six weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One-time implementation intention
Description: Will only be given the intervention once

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Canada's Food Guide for Healthy Eating will be provided. This contains a small amount of physical activity information.